Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-08-04

Clinical Trial Update: Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluated the efficacy, safety, and tolerability of a novel malathion formulation for head lice in patients aged 2 years and older. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Malathion (novel formulation) (malathion)

Snippet

Sponsor: Sun Pharmaceutical Industries, Inc. | Conditions: Pediculosis | Phase 3 | Status: COMPLETED | Results posted: 2014-08-04